German producer prices rise 0.7% in February - Breaking The News
Download our appPlay StoreApp Store

German producer prices rise 0.7% in February

EPA / INGO WAGNER

Producer prices in Germany grew by 0.7% in February, the country's statistical office Destatis revealed in a report on Thursday. The index declined 0.2% month-over-month.

In the reported month, the annual increase in producer prices was primarily driven by higher costs for non-durable consumer goods, which rose 3% year-over-year. Food prices saw a notable increase of 3.5% in January, while durable consumer goods prices climbed by 1.2%. Additionally, capital goods prices registered a 2% increase compared to February 2024.

Meanwhile, energy prices declined by 0.8% year-over-year and decreased by 1% compared to January.

Related Stocks
General Motors
Related News
Moderna's Q3 revenue slumps 45% to $1.0 billion
Moderna Inc. revealed on Thursday that its total revenue for the third quarter of fiscal 2025 landed at $1.0 billion, declining 45% from the same period a year ago. The drop was largely attributed to an $847 million, or 47%, fall in net product sales, primarily reflecting reduced demand for COVID vaccines.In the reported period, the biotechnology giant reported a $200 million net loss, compared with a profit of $13 million a year earlier. Its diluted loss per share...
Pfizer, Novo Nordisk said to raise bids for Metsera
Pfizer and Novo Nordisk both raised their bids for US biotech Metsera, escalating one of the fiercest takeover battles in the obesity-drug sector. The Financial Times reported on Tuesday that the improved offers from both companies are expected to be disclosed in a regulatory filing later in the day.Novo Nordisk last week topped Pfizer's earlier agreement with a proposal worth up to $9 billion, triggering a legal and commercial standoff between the two...
Pfizer reports Q3 sales of $16.7 billion, down 6%
Pfizer Inc. announced on Tuesday that its revenue for the third quarter of 2025 fell by 6% annually to $16.7 billion. Net income dropped 21% to $3.5 billion, while the diluted earnings per share (EPS) also lost 21% year-on-year, landing at $0.62. The pharma giant reaffirmed its full-year 2025 revenue guidance of $61 billion to $64 billion and raised its diluted EPS outlook to between $3 and $3.15."I am proud of Pfizer's leadership as the first in our industry to reach an...
Pfizer files second lawsuit against Metsera, Novo Nordisk
Pfizer Inc. said on Monday that it filed a second lawsuit against Metsera Inc., its controlling stockholders, and Novo Nordisk A/S, claiming that Novo Nordisk conspired with Metsera and engaged in anticompetitive behavior when it proposed to acquire it. Pfizer first struck a deal to buy Metsera in September, but the obesity drug company then received an offer from Novo Nordisk last week and deemed it superior to Pfizer's. Pfizer then sued both companies on...

Please observe our Terms of Use. The price information is time delayed to varying extents, but as a rule by 15 minutes or more, according to the regulations of the selected stock exchange and/or licensors and the type of securities.

© 2025 TeleTrader Software GmbH. All rights reserved

This website uses cookies to ensure you get the best experience. Our Terms of Use and Data Protection Policy explain the data we collect, why we collect them, and how we may share them.